Pharmacological management of connective tissue disease-associated pulmonary arterial hypertension

References

• Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2022;61:2200879. doi: 10.1183/13993003.00879-2022
   Web of Science ®Google Scholar
• Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022 [2022 Oct 11];43(38):3618–3731. doi: 10.1093/eurheartj/ehac237
   PubMed Web of Science ®Google Scholar
• Humbert M, Guignabert C, Bonnet S, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2019 Jan;53(1):1801887. doi: 10.1183/13993003.01887-2018
   PubMed Web of Science ®Google Scholar
• Lau EMT, Giannoulatou E, Celermajer DS, et al. Epidemiology and treatment of pulmonary arterial hypertension. Nat Rev Cardiol. 2017 Oct;14(10):603–614. doi: 10.1038/nrcardio.2017.84
   PubMed Web of Science ®Google Scholar
• Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest. 2010 Dec;138(6):1383–1394. doi: 10.1378/chest.10-0260
   PubMed Web of Science ®Google Scholar
• Fayed H, Coghlan JG. Pulmonary hypertension associated with connective tissue disease. Semin Respir Crit Care Med. 2019 Apr;40(2):173–183. doi: 10.1055/s-0039-1685214
   PubMed Web of Science ®Google Scholar
• Launay D, Sobanski V, Hachulla E, et al. Pulmonary hypertension in systemic sclerosis: different phenotypes. Eur Respir Rev. 2017 Sep 30;26(145):170056. doi: 10.1183/16000617.0056-2017
   PubMed Web of Science ®Google Scholar
• Johnson SR, Granton JT. Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus. Eur Respir Rev. 2011 Dec;20(122):277–286. doi: 10.1183/09059180.00003811
   PubMedGoogle Scholar
• Vonk MC, Vandecasteele E, van Dijk AP. Pulmonary hypertension in connective tissue diseases, new evidence and challenges. Eur J Clin Invest. 2021 Apr;51(4):e13453. doi: 10.1111/eci.13453
   PubMed Web of Science ®Google Scholar
• Montani D, Henry J, O’Connell C, et al. Association between rheumatoid arthritis and pulmonary hypertension: data from the French pulmonary hypertension registry. Respiration. 2018;95(4):244–250. doi: 10.1159/000485631
   PubMed Web of Science ®Google Scholar
• Khanna D, Zhao C, Saggar R, et al. Long-term outcomes in patients with connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era: meta-analyses of randomized, controlled trials and observational registries. Arthritis & rheumat. 2021 May;73(5):837–847. doi: 10.1002/art.41669
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, D’Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013 Jul 25;369(4):319–329. doi: 10.1056/NEJMoa1209657
   PubMed Web of Science ®Google Scholar
• Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med. 2021;384(4):325–334. doi: 10.1056/NEJMoa2008470
   PubMed Web of Science ®Google Scholar
• Ahmed S, Palevsky HI. Pulmonary arterial hypertension related to connective tissue disease: a review. Rheum Dis Clin North Am. 2014 Feb;40(1):103–124. doi: 10.1016/j.rdc.2013.10.001
   PubMed Web of Science ®Google Scholar
• Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009 Jan 15;179(2):151–157. doi: 10.1164/rccm.200806-953OC
   PubMed Web of Science ®Google Scholar
• Jeon CH, Chai JY, Seo YI, et al. Pulmonary hypertension associated with rheumatic diseases: baseline characteristics from the Korean registry. Int J Rheum Dis. 2012 Oct;15(5):e80–9. doi: 10.1111/j.1756-185X.2012.01815.x
   PubMed Web of Science ®Google Scholar
• Hao YJ, Jiang X, Zhou W, et al. Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients. Eur Respir J. 2014 Oct;44(4):963–972. doi: 10.1183/09031936.00182813
   PubMed Web of Science ®Google Scholar
• Shirai Y, Yasuoka H, Okano Y, et al. Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a single-centre cohort. Rheumatology (Oxford). 2012 Oct;51(10):1846–1854. doi: 10.1093/rheumatology/kes140
   PubMed Web of Science ®Google Scholar
• Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007 Jul;66(7):940–944. doi: 10.1136/ard.2006.066068
   PubMed Web of Science ®Google Scholar
• Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003 Nov;62(11):1088–1093. doi: 10.1136/ard.62.11.1088
   PubMed Web of Science ®Google Scholar
• Morrisroe K, Stevens W, Sahhar J, et al. Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme. Arthritis Res Ther. 2017 Mar 7;19(1):42. doi: 10.1186/s13075-017-1250-z
   PubMedGoogle Scholar
• Weatherald J, Montani D, Jevnikar M, et al. Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev. 2019 Sep 30;28(153):190023. doi: 10.1183/16000617.0023-2019
   PubMed Web of Science ®Google Scholar
• Humbert M, Yaici A, de Groote P, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum. 2011 Nov;63(11):3522–3530. doi: 10.1002/art.30541
   PubMed Web of Science ®Google Scholar
• Joven BE, Escribano P, Andreu JL, et al. 2013 ACR/EULAR systemic sclerosis classification criteria in patients with associated pulmonary arterial hypertension. Semin Arthritis Rheum. 2018 Jun;47(6):870–876.
   PubMed Web of Science ®Google Scholar
• Demerouti E, Tsangaris I, Dimitroulas T, et al. Pulmonary arterial hypertension in connective tissue disorders: the emerging role of screening and early diagnosis. A position paper for Greek rheumatologists. Mediterr J Rheumatol. 2019 Jun;30(2):90–93. doi: 10.31138/mjr.30.2.90
   PubMedGoogle Scholar
• Coghlan JG, Denton CP, Grunig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014 Jul;73(7):1340–1349. doi: 10.1136/annrheumdis-2013-203301
   PubMed Web of Science ®Google Scholar
• Thakkar V, Stevens W, Prior D, et al. The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study. Arthritis Res Ther. 2013;15(6):R193. doi: 10.1186/ar4383
   PubMed Web of Science ®Google Scholar
• Hachulla E, Jais X, Cinquetti G, et al. Pulmonary arterial hypertension associated with systemic lupus erythematosus: results from the French pulmonary hypertension registry. Chest. 2018 Jan;153(1):143–151. doi: 10.1016/j.chest.2017.08.014
   PubMed Web of Science ®Google Scholar
• Chen HA, Hsu TC, Yang SC, et al. Incidence and survival impact of pulmonary arterial hypertension among patients with systemic lupus erythematosus: a nationwide cohort study. Arthritis Res Ther. 2019 Mar 27;21(1):82. doi: 10.1186/s13075-019-1868-0
   PubMedGoogle Scholar
• Perez-Penate GM, Rua-Figueroa I, Julia-Serda G, et al. Pulmonary arterial hypertension in systemic lupus erythematosus: prevalence and predictors. J Rheumatol. 2016 Feb;43(2):323–329. doi: 10.3899/jrheum.150451
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Garmendia M, Villar I, et al. Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. Autoimmun Rev. 2013 Jan;12(3):410–415. doi: 10.1016/j.autrev.2012.07.010
   PubMed Web of Science ®Google Scholar
• Thakkar V, Lau EM. Connective tissue disease-related pulmonary arterial hypertension. Best Pract Res Clin Rheumatol. 2016 Feb;30(1):22–38. doi: 10.1016/j.berh.2016.03.004
   PubMed Web of Science ®Google Scholar
• Delcroix M, Torbicki A, Gopalan D, et al. ERS statement on chronic thromboembolic pulmonary hypertension. Eur Respir J. 2021 Jun;57(6):2002828. doi: 10.1183/13993003.02828-2020
   PubMed Web of Science ®Google Scholar
• Hachulla E, de Groote P, Gressin V, et al. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum. 2009 Jun;60(6):1831–1839. doi: 10.1002/art.24525
   PubMed Web of Science ®Google Scholar
• Rich JD, Rich S. Clinical diagnosis of pulmonary hypertension. Circulation. 2014 Nov 11;130(20):1820–1830. doi: 10.1161/CIRCULATIONAHA.114.006971
   PubMed Web of Science ®Google Scholar
• Solomon JJ, Olson AL, Fischer A, et al. Scleroderma lung disease. Eur Respir Rev. 2013 Mar 1;22(127):6–19. doi: 10.1183/09059180.00005512
   PubMedGoogle Scholar
• Shellenberger RA, Imtiaz K, Chellappa N, et al. Physical examination for the detection of pulmonary hypertension: a systematic review. Cureus. 2021 Sep;13(9):e18020. doi: 10.7759/cureus.18020
   PubMed Web of Science ®Google Scholar
• Minopoulou I, Theodorakopoulou M, Boutou A, et al. Nailfold Capillaroscopy in systemic sclerosis patients with and without pulmonary arterial hypertension: a systematic review and meta-analysis. J Clin Med. 2021 Apr 6;10(7):1528. doi: 10.3390/jcm10071528
   PubMed Web of Science ®Google Scholar
• Pena E, Dennie C, Veinot J, et al. Pulmonary hypertension: how the radiologist can help. Radiographics. 2012 Jan;32(1):9–32. doi: 10.1148/rg.321105232
   PubMed Web of Science ®Google Scholar
• Wang M, Wu D, Ma R, et al. Comparison of V/Q SPECT and CT angiography for the diagnosis of chronic thromboembolic pulmonary hypertension. Radiology. 2020 Aug;296(2):420–429. doi: 10.1148/radiol.2020192181
   PubMed Web of Science ®Google Scholar
• Lee JJ, Pope JE. A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. Arthritis Res Ther. 2014 Sep 25;16(5):435. doi: 10.1186/s13075-014-0435-y
   PubMed Web of Science ®Google Scholar
• Trip P, Nossent EJ, de Man FS, et al. Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses. Eur Respir J. 2013 Dec;42(6):1575–1585. doi: 10.1183/09031936.00184412
   PubMed Web of Science ®Google Scholar
• Schwaiger JP, Khanna D, Gerry Coghlan J. Screening patients with scleroderma for pulmonary arterial hypertension and implications for other at-risk populations. Eur Respir Rev. 2013 Dec;22(130):515–525. doi: 10.1183/09059180.00006013
   PubMedGoogle Scholar
• Dimitroulas T, Giannakoulas G, Papadopoulou K, et al. Left atrial volume and N-terminal pro-B type natriuretic peptide are associated with elevated pulmonary artery pressure in patients with systemic sclerosis. Clin Rheumatol. 2010 Sep;29(9):957–964. doi: 10.1007/s10067-010-1494-3
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005 Jun 14;111(23):3105–3111. doi: 10.1161/CIRCULATIONAHA.104.488486
   PubMed Web of Science ®Google Scholar
• Montani D, Savale L, Natali D, et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J. 2010 Aug;31(15):1898–1907. doi: 10.1093/eurheartj/ehq170
   PubMed Web of Science ®Google Scholar
• Kovacs G, Herve P, Barbera JA, et al. An official European Respiratory Society statement: pulmonary haemodynamics during exercise. Eur Respir J. 2017 Nov;50(5):1700578. doi: 10.1183/13993003.00578-2017
   PubMed Web of Science ®Google Scholar
• Hjalmarsson C, Kjellstrom B, Jansson K, et al. Early risk prediction in idiopathic versus connective tissue disease-associated pulmonary arterial hypertension: call for a refined assessment. ERJ Open Res. 2021 Jul;7(3):00854–2020. doi: 10.1183/23120541.00854-2020
   PubMedGoogle Scholar
• Rhee RL, Gabler NB, Praestgaard A, et al. Adverse events in connective tissue disease-associated pulmonary arterial hypertension. Arthritis & rheumat. 2015 Sep;67(9):2457–2465. doi: 10.1002/art.39220
   PubMed Web of Science ®Google Scholar
• Launay D, Sitbon O, Le Pavec J, et al. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology (Oxford). 2010 Mar;49(3):490–500. doi: 10.1093/rheumatology/kep398
   PubMed Web of Science ®Google Scholar
• Hassoun PM, Zamanian RT, Damico R, et al. Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2015 Nov 1;192(9):1102–1110. doi: 10.1164/rccm.201507-1398OC
   PubMed Web of Science ®Google Scholar
• Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000 Mar 21;132(6):425–434. doi: 10.7326/0003-4819-132-6-200003210-00002
   PubMed Web of Science ®Google Scholar
• Otair HAA, Hajjaj MSA, Alhamad EH, et al. Iloprost as adjuvant to sildenafil in connective tissue disease-associated pulmonary hypertension. Turk Thorac J. 2013. doi: 10.5152/ttd.2013.19.
   Google Scholar
• Weitzenblum E, Sautegeau A, Ehrhart M, et al. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1985 Apr;131(4):493–498. doi: 10.1164/arrd.1985.131.4.493
   PubMed Web of Science ®Google Scholar
• Stickel S, Gin-Sing W, Wagenaar M, et al. The practical management of fluid retention in adults with right heart failure due to pulmonary arterial hypertension. Eur Heart J Suppl. 2019 Dec;21(Suppl K):K46–K53. doi: 10.1093/eurheartj/suz207
   PubMed Web of Science ®Google Scholar
• Grunig E, MacKenzie A, Peacock AJ, et al. Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial. Eur Heart J. 2021 Jun 14;42(23):2284–2295. doi: 10.1093/eurheartj/ehaa696
   PubMed Web of Science ®Google Scholar
• Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the national heart, lung, and blood Institute, primary pulmonary hypertension registry. Circulation. 1989 Nov;80(5):1198–1206. doi: 10.1161/01.CIR.80.5.1198
   PubMed Web of Science ®Google Scholar
• Wang P, Hu L, Yin Y, et al. Can anticoagulants improve the survival rate for patients with idiopathic pulmonary arterial hypertension? A systematic review and meta-analysis. Thromb Res. 2020 Dec;196:251–256.
   PubMed Web of Science ®Google Scholar
• Olsson KM, Delcroix M, Ghofrani HA, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the comparative, prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA). Circulation. 2014 Jan 7;129(1):57–65. doi: 10.1161/CIRCULATIONAHA.113.004526
   PubMed Web of Science ®Google Scholar
• Preston IR, Roberts KE, Miller DP, et al. Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the registry to evaluate early and Long-term PAH disease management (REVEAL). Circulation. 2015 Dec 22;132(25):2403–2411. doi: 10.1161/CIRCULATIONAHA.115.018435
   PubMed Web of Science ®Google Scholar
• Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992 Jul 9;327(2):76–81. doi: 10.1056/NEJM199207093270203
   PubMed Web of Science ®Google Scholar
• Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005 Nov 17;353(20):2148–2157. doi: 10.1056/NEJMoa050010
   PubMed Web of Science ®Google Scholar
• Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995 Jul 27;333(4):214–221. doi: 10.1056/NEJM199507273330403
   PubMed Web of Science ®Google Scholar
• Wharton J, Strange JW, Moller GM, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med. 2005 Jul 1;172(1):105–113. doi: 10.1164/rccm.200411-1587OC
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Fleming TR, et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest. 2011 Nov;140(5):1274–1283. doi: 10.1378/chest.10-0969
   PubMed Web of Science ®Google Scholar
• Badesch DB, Hill NS, Burgess G, et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol. 2007;34(12):2417–2422.
   PubMed Web of Science ®Google Scholar
• Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009 Jun 9;119(22):2894–2903. doi: 10.1161/CIRCULATIONAHA.108.839274
   PubMed Web of Science ®Google Scholar
• Galie N, Denton CP, Dardi F, et al. Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease. Int J Cardiol. 2017 May 15;235:67–72. doi: 10.1016/j.ijcard.2017.02.094
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Galie N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013 Jul 25;369(4):330–340. doi: 10.1056/NEJMoa1209655
   PubMed Web of Science ®Google Scholar
• Humbert M, Coghlan JG, Ghofrani HA, et al. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis. 2017 Feb;76(2):422–426. doi: 10.1136/annrheumdis-2015-209087
   PubMed Web of Science ®Google Scholar
• MacLean MR. Endothelin-1: a mediator of pulmonary hypertension? Pulm Pharmacol Ther. 1998 Apr;11(2–3):125–132. doi: 10.1006/pupt.1998.0126
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002 Mar 21;346(12):896–903. doi: 10.1056/NEJMoa012212
   PubMed Web of Science ®Google Scholar
• Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001 Oct 6;358(9288):1119–1123. doi: 10.1016/S0140-6736(01)06250-X
   PubMed Web of Science ®Google Scholar
• Denton CP, Humbert M, Rubin L, et al. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis. 2006 Oct;65(10):1336–1340. doi: 10.1136/ard.2005.048967
   PubMed Web of Science ®Google Scholar
• Girgis RE, Mathai SC, Krishnan JA, et al. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant. 2005 Oct;24(10):1626–1631. doi: 10.1016/j.healun.2004.12.113
   PubMed Web of Science ®Google Scholar
• Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809–818. doi: 10.1056/NEJMoa1213917
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Channick R, Kim NH, et al. Safety of macitentan for the treatment of pulmonary hypertension: real-world experience from the OPsumit(R) USers registry (OPUS) and OPsumit(R) historical USers cohort (OrPheus). Pulm Circ. 2022 Oct;12(4):e12150. doi: 10.1002/pul2.12150
   PubMed Web of Science ®Google Scholar
• Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008 Jun 10;117(23):3010–3019. doi: 10.1161/CIRCULATIONAHA.107.742510
   PubMed Web of Science ®Google Scholar
• Fischer A, Denton CP, Matucci-Cerinic M, et al. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - a subgroup analysis of the ARIES-E clinical trial. Respir med. 2016 Aug;117:254–263.
   PubMed Web of Science ®Google Scholar
• Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med. 1990 Jul 5;323(1):27–36. doi: 10.1056/NEJM199007053230106
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996 Feb 1;334(5):296–301. doi: 10.1056/NEJM199602013340504
   PubMed Web of Science ®Google Scholar
• Badesch DB, McGoon MD, Barst RJ, et al. Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J Rheumatol. 2009 Oct;36(10):2244–2249. doi: 10.3899/jrheum.081277
   PubMed Web of Science ®Google Scholar
• Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002 Mar 15;165(6):800–804. doi: 10.1164/ajrccm.165.6.2106079
   PubMed Web of Science ®Google Scholar
• Oudiz RJ, Schilz RJ, Barst RJ, et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest. 2004 Aug;126(2):420–427. doi: 10.1378/chest.126.2.420
   PubMed Web of Science ®Google Scholar
• Tapson VF, Gomberg-Maitland M, McLaughlin VV, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest. 2006 Mar;129(3):683–688. doi: 10.1378/chest.129.3.683
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010 May 4;55(18):1915–1922. doi: 10.1016/j.jacc.2010.01.027
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Channick R, De Marco T, et al. Results of an expert consensus survey on the treatment of pulmonary arterial hypertension with oral prostacyclin pathway agents. Chest. 2020 Apr;157(4):955–965. doi: 10.1016/j.chest.2019.10.043
   PubMed Web of Science ®Google Scholar
• White RJ, Jerjes-Sanchez C, Bohns Meyer GM, et al. Combination therapy with oral treprostinil for pulmonary arterial hypertension. A Double-blind placebo-controlled clinical trial. Am J Respir Crit Care Med. 2020 Mar 15;201(6):707–717. doi: 10.1164/rccm.201908-1640OC
   PubMed Web of Science ®Google Scholar
• Higenbottam TW, Butt AY, Dinh-Xaun AT, et al. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart. 1998 Feb;79(2):175–179. doi: 10.1136/hrt.79.2.175
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Gall H, Seyfarth HJ, et al. Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. Eur Respir J. 2009 Jul;34(1):132–137. doi: 10.1183/09031936.00130408
   PubMed Web of Science ®Google Scholar
• Olschewski H. Inhaled iloprost for the treatment of pulmonary hypertension. Eur Respir Rev. 2009 Mar;18(111):29–34. doi: 10.1183/09059180.00011111
   PubMedGoogle Scholar
• Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015 Dec 24;373(26):2522–2533. doi: 10.1056/NEJMoa1503184
   PubMed Web of Science ®Google Scholar
• Gaine S, Chin K, Coghlan G, et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J. 2017 Aug;50(2):1602493. doi: 10.1183/13993003.02493-2016
   PubMed Web of Science ®Google Scholar
• Sitbon O, Sattler C, Bertoletti L, et al. Initial dual oral combination therapy in pulmonary arterial hypertension. Eur Respir J. 2016 Jun;47(6):1727–1736. doi: 10.1183/13993003.02043-2015
   PubMed Web of Science ®Google Scholar
• Pan J, Lei L, Zhao C. Comparison between the efficacy of combination therapy and monotherapy in connective tissue disease associated pulmonary arterial hypertension: a systematic review and meta-analysis. Clin Exp Rheumatol. 2018 Nov;36(6):1095–1102.
   PubMed Web of Science ®Google Scholar
• Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004 Sep;24(3):353–359. doi: 10.1183/09031936.04.00028404
   PubMed Web of Science ®Google Scholar
• Galie N, Barbera JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015 Aug 27;373(9):834–844. doi: 10.1056/NEJMoa1413687
   PubMed Web of Science ®Google Scholar
• Coghlan JG, Galie N, Barbera JA, et al. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis. 2017 Jul;76(7):1219–1227. doi: 10.1136/annrheumdis-2016-210236
   PubMed Web of Science ®Google Scholar
• Sitbon O, Cottin V, Canuet M, et al. Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. Eur Respir J. 2020 Sep;56(3):2000673. doi: 10.1183/13993003.00673-2020
   PubMed Web of Science ®Google Scholar
• Mathai SC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J. 2007 Mar;29(3):469–475. doi: 10.1183/09031936.00081706
   PubMed Web of Science ®Google Scholar
• Dardi F, Manes A, Palazzini M, et al. Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights. Eur Respir J. 2015 Aug;46(2):414–421. doi: 10.1183/09031936.00209914
   PubMed Web of Science ®Google Scholar
• Weatherald J, Thakrar MV, Varughese RA, et al. Upfront riociguat and ambrisentan combination therapy for newly diagnosed pulmonary arterial hypertension: a prospective open-label trial. J Heart Lung Transplant. 2022 May;41(5):563–567. doi: 10.1016/j.healun.2022.01.002
   PubMed Web of Science ®Google Scholar
• Sulica R, Sangli S, Chakravarti A, et al. Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension. Pulm Circ. 2019 Jan;9(1):2045894019826944. doi: 10.1177/2045894019826944
   Web of Science ®Google Scholar
• Chin KM, Sitbon O, Doelberg M, et al. Three- versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension. J Am Coll Cardiol. 2021 Oct 5;78(14):1393–1403. doi: 10.1016/j.jacc.2021.07.057
   PubMed Web of Science ®Google Scholar
• Hassan HJ, Naranjo M, Ayoub N, et al. Improved survival for patients with systemic sclerosis-associated pulmonary arterial hypertension: the Johns Hopkins registry. Am J Respir Crit Care Med. 2023 Feb 1;207(3):312–322. doi: 10.1164/rccm.202204-0731OC
   PubMed Web of Science ®Google Scholar
• Perros F, Humbert M, Dorfmuller P. Smouldering fire or conflagration? An illustrated update on the concept of inflammation in pulmonary arterial hypertension. Eur Respir Rev. 2021 Dec 31;30(162):210161. doi: 10.1183/16000617.0161-2021
   PubMed Web of Science ®Google Scholar
• Dorfmuller P, Perros F, Balabanian K, et al. Inflammation in pulmonary arterial hypertension. Eur Respir J. 2003 Aug;22(2):358–363. doi: 10.1183/09031936.03.00038903
   PubMed Web of Science ®Google Scholar
• Sanchez O, Sitbon O, Jais X, et al. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest. 2006 Jul;130(1):182–189. doi: 10.1378/chest.130.1.182
   PubMed Web of Science ®Google Scholar
• Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum. 2008 Feb;58(2):521–531. doi: 10.1002/art.23303
   PubMed Web of Science ®Google Scholar
• Zamanian RT, Badesch D, Chung L, et al. Safety and efficacy of B-Cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension: a multicenter, Double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2021 Jul 15;204(2):209–221. doi: 10.1164/rccm.202009-3481OC
   PubMed Web of Science ®Google Scholar
• Hoffmann-Vold AM, Petelytska L, Fretheim H, et al. OP0236 risk factors for SSc-ILD progression using the new PPF guideline and inbuild PF-ILD criteria. Ann Rheumatic Dis. 2023;82(Suppl 1):156–157.
   Google Scholar
• Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J Med. 2021 Apr 1;384(13):1204–1215. doi: 10.1056/NEJMoa2024277
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Badesch DB, Ghofrani HA, et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023 Mar 6;388(16):1478–1490. doi: 10.1056/NEJMoa2213558
   PubMed Web of Science ®Google Scholar
• Leard LE, Holm AM, Valapour M, et al. Consensus document for the selection of lung transplant candidates: an update from the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2021 Nov;40(11):1349–1379. doi: 10.1016/j.healun.2021.07.005
   PubMed Web of Science ®Google Scholar
• Crespo MM, Bermudez CA, Dew MA, et al. Lung transplant in patients with scleroderma compared with pulmonary fibrosis. Short- and Long-term outcomes. Ann Am Thorac Soc. 2016 Jun;13(6):784–792. doi: 10.1513/AnnalsATS.201503-177OC
   PubMed Web of Science ®Google Scholar
• Courtwright AM, El-Chemaly S, Dellaripa PF, et al. Survival and outcomes after lung transplantation for non-scleroderma connective tissue-related interstitial lung disease. J Heart Lung Transplant. 2017 Jul;36(7):763–769. doi: 10.1016/j.healun.2016.12.013
   PubMed Web of Science ®Google Scholar
• Al Maluli H, DeStephan CM, Alvarez RJ Jr., et al. Atrial septostomy: a contemporary review. Clinical Cardiology. 2015 Jun;38(6):395–400. doi: 10.1002/clc.22398
   PubMed Web of Science ®Google Scholar
• Kylhammar D, Kjellstrom B, Hjalmarsson C, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2018 Dec 14;39(47):4175–4181. doi: 10.1093/eurheartj/ehx257
   PubMed Web of Science ®Google Scholar
• Mullin CJ, Khair RM, Damico RL, et al. Validation of the REVEAL prognostic equation and risk score calculator in Incident systemic sclerosis-associated pulmonary arterial hypertension. Arthritis & Rheumat. 2019 Oct;71(10):1691–1700. doi: 10.1002/art.40918
   PubMed Web of Science ®Google Scholar
• Mercurio V, Diab N, Peloquin G, et al. Risk assessment in scleroderma patients with newly diagnosed pulmonary arterial hypertension: application of the ESC/ERS risk prediction model. Eur Respir J. 2018 Oct;52(4):1800497. doi: 10.1183/13993003.00497-2018
   PubMed Web of Science ®Google Scholar
• Chauvelot L, Gamondes D, Berthiller J, et al. Hemodynamic response to treatment and outcomes in pulmonary hypertension associated with interstitial lung disease versus pulmonary arterial hypertension in systemic sclerosis: data from a study identifying prognostic factors in pulmonary hypertension associated with interstitial lung disease. Arthritis & Rheumat. 2021 Feb;73(2):295–304. doi: 10.1002/art.41512
   PubMed Web of Science ®Google Scholar